

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**LEPU BIOPHARMA CO., LTD.**  
**樂普生物科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2157)**

**SUPPLEMENTAL NOTICE OF THE POSTPONED 2022 FIRST EXTRAORDINARY  
GENERAL MEETING**

Reference is made to the notice of the 2022 First Extraordinary General Meeting (the “EGM”) of Lepu Biopharma Co., Ltd. (the “Company”) dated September 1, 2022 (the “Original Notice of EGM”) which sets out details of the resolutions to be considered by the shareholders of the Company (the “Shareholders”) at the EGM originally scheduled to be held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, PRC on Friday, September 16, 2022 at 10 a.m.. This supplemental notice shall be read together with the Original Notice of EGM.

Save for resolutions under items numbered 1(v), 1(x) and 2, which have been deleted and replaced by the new resolutions with details set out below, details of the proposed resolutions to be considered at the Postponed EGM (as defined below) were stated in the Original Notice of EGM. Unless otherwise stated, terms defined herein shall have the same meanings as those defined in the circular of the Company dated September 1, 2022. Apart from the amendment stated below, all the information contained in the Original Notice of EGM remains to be valid and effective.

**SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT** the EGM will be postponed and held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, PRC on Friday, September 23, 2022 at 5:00 p.m. (the “Postponed EGM”) and the resolutions under items numbered 1(v), 1(x) and 2 stated in the Original Notice of EGM should be deleted in its entirety and replaced by the following new resolutions under items number 1(v), 1(x) and 2:

**SPECIAL RESOLUTIONS**

- “1. To consider and approve the proposed Issue of A shares as follows (each and every item as a separate resolution):
  - v. Pricing methodology: The issue price for the A Shares will be determined by the Company (on the basis of Shareholders’ authorization) and the lead underwriter on the basis of the results of the enquiry from the price consultation participants who meet the conditions stipulated by the CSRC in accordance with applicable laws and regulations, or by other pricing methods recognized by the CSRC and the Shanghai Stock Exchange.

Based on the PRC Company Law, the issue price of the A Shares shall not be lower than the nominal value of the Shares of the Company, i.e. RMB1.00 per Share. There is no other legal or regulatory requirements stipulating the price floor in the Issue of A Shares. As at June 30, 2022, the net asset value per Share of the Company was RMB0.75. The Company does not intend to issue the A Shares at a price lower than the higher of (i) the latest audited net asset value per Share prior to the proposed Issue of A Shares, and (ii) the nominal value of the Shares of the Company.

As at the Latest Practicable Date, the closing price per H Share as quoted on the Stock Exchange is HK\$7.07 per H Share.

- x. Validity period of the resolutions: The resolutions will be valid for a period of 12 months from the date of approval at the Postponed EGM and the Postponed Class Meetings.”
- “2. To consider and approve the authorization to the Board of Directors and persons authorized by it to fully handle the relevant matters in connection with the Issue of A Shares and the listing on the Sci-Tech Board.

The authorization proposed to be granted to the Board and persons authorized by it shall include without limitation:

- i. The formulation, implementation, and adjustment of the specific proposals for the Issue of A Shares and listing on the Sci-Tech Board, including but not limited to specific matters such as the decision on whether any placing is made to strategic investors or the adoption of the over-allotment option, in accordance with laws and regulations, the relevant requirements of securities regulatory authorities, and the resolutions passed by the Shareholders at the Postponed EGM and Postponed Class Meetings.
- ii. The filing of application for the Issue of A Shares and listing on the Sci-Tech Board to the CSRC and the Shanghai Stock Exchange, and the response to comments from the CSRC and the Shanghai Stock Exchange.
- iii. The determination of the specific details of the Issue of A Shares and listing on the Sci-Tech Board including the schedule of issuance, issue size, method of issuance, issue price and pricing methodology, target subscribers, and method of subscription in accordance with the requirements of securities regulatory authorities and the actual circumstances of the securities market.
- iv. The appropriate adjustments to be made to the investment projects to be funded by the proceeds raised and the investment amount according to the implementation process of the Issue of A Shares, market conditions, relevant policies and requirements of the relevant securities regulatory authorities. The determination of the progress of investment projects to be funded by the proceeds raised, the allocation of funds when applying the proceeds raised, and entering into material contracts relating to the operational process of the investment projects.

- v. The appropriate adjustment to the specific matters relating to the Issue of A Shares and listing on the Sci-Tech Board within the effective period for the Issue of A Shares, including the amendment and submission of listing application materials as required by a change of policies or market circumstances, and unless such change involves matters that would necessitate authorization at another general meeting pursuant to relevant laws, regulations and the Articles.
- vi. Undertaking reporting and procedural work to the relevant government authorities in relation to the Issue of A Shares and listing on the Sci-Tech Board, including but not limited to the application for approval, registration, filing, or consent to the relevant government authorities, regulatory authorities, stock exchanges, securities registration and settlement organizations, as well as the signing, execution, amendment, and completion of all necessary documents in relation to the Issue of A Shares.
- vii. After the completion of the Issue of A Shares and listing on the Sci-Tech Board, the amendments of the Articles, capital verification, commercial registration changes and relevant approvals, registrations and filings.
- viii. After the completion of the Issue of A Shares and listing on the Sci-Tech Board, in accordance with the undertakings of each Shareholder, handling matters of registration and settlement of shareholdings at the China Securities Depository and Clearing Co., Ltd., including but not limited to the depository, registration, circulation and lock-up of Shares.
- ix. The authorization to handle matters in relation to the opening of the depository account for the funds raised.
- x. To the extent permitted by relevant laws, regulations, requirements of relevant securities regulatory authorities and resolutions of the Postponed EGM and Postponed Class Meetings, the handling of other matters considered to be necessary for the Issue of A Shares and listing on the Sci-Tech Board.

The above authorization, if approved, shall be valid for a period of 12 months from the date of approval at the Postponed EGM and the Postponed Class Meetings.”

By order of the Board  
**Lepu Biopharma Co., Ltd.**  
**Dr. Pu Zhongjie**

*Chairman of the Board and Executive Director*

Shanghai, the PRC,  
September 8, 2022

*Notes:*

1. All resolutions at the Postponed EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Company at [www.lepubiopharma.com](http://www.lepubiopharma.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) after the Postponed EGM.
2. For more information of the other resolutions to be considered at the Postponed EGM, please refer to the original circular of the Company dated September 1, 2022 (the “**Original Circular**”) and the supplemental circular of the Company dated September 8, 2022 (the “**Supplemental Circular**”).
3. Any Shareholder entitled to attend and vote at the Postponed EGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a Shareholder of the Company.
4. Since the proxy form for the EGM which was dispatched to Shareholders on September 1, 2022 (the “**Original Proxy Form**”) does not contain the resolutions in the form as set out in this Supplemental Notice of the Postponed EGM, a new form of proxy (the “**Revised Proxy Form**”) has been prepared and is enclosed with this Supplemental Notice of the Postponed EGM.
5. **In view of the ongoing COVID-19 pandemic, the Company strongly recommends Shareholders of the Company to exercise your voting rights by appointing the chairman of the Postponed EGM as your proxy to vote on the relevant resolution(s) at the Postponed EGM as an alternative to attending the Postponed EGM in person.**
6. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company’s headquarters and registered office in the PRC (for Domestic Shareholders) or the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong (for H Shareholders), at least 24 hours before the Postponed EGM (i.e. not later than 5:00 p.m. on Thursday, September 22, 2022) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the Postponed EGM or any adjourned meeting thereof should he/she so wish.
7. As disclosed in the Supplemental Circular, due to the postponement of the EGM, for the purpose of determining the list of H Shareholders who are entitled to attend and vote at the Postponed EGM, the closure period of the register of members of the Company will be extended from the period commencing on Wednesday, August 17, 2022 to Friday, September 16, 2022 (both days inclusive) to the period from Wednesday, August 17, 2022 to Friday, September 23, 2022 (both dates inclusive), during which period no transfer of H Shares will be registered. Accordingly, in order to be eligible for attending and voting at the Postponed EGM, all properly completed transfer documents accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Tuesday, August 16, 2022.
8. Where there are joint registered holders of any Share, any one of such joint holders may vote, either in person or by proxy, in respect of such Share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the Postponed EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the Shares shall alone be entitled to vote in respect thereof.
9. A Shareholder or his/her proxy should produce proof of identity when attending the Postponed EGM.
10. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.

*As at the date of this notice, the Board comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziyue (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.*